Class summary at a glance.

Every drug in the Calcium Channel Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $467.4Mcombined across class
Total Rx claims: 12.1M4.1M unique beneficiaries
Generic mfrs (active): 43across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Diltiazem

Brand: CARTIA XT · 9.7M Part D claims (CY24) · 3.3M beneficiaries · First FDA approval: 1992-11-05

24 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.053

→

Avg plan cost$0.727

Part D spend $343.4M 14× spread, current vs floor

Class share

73%

of class CY24 spend

View profile →

Verapamil

Brand: VERELAN PM · 2.4M Part D claims (CY24) · 768K beneficiaries · First FDA approval: 1986-10-01

19 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.063

→

Avg plan cost$1.89

Part D spend $124.0M 30× spread, current vs floor

Class share

27%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.